Newsfile Corp
05 Sept 2026, 17:15 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 Trial of Fianlimab failed to reach statistical significance for its primary endpoint of improvement in progression-free survival (PFS). — Failure of a Phase 3 clinical trial is a major setback for a drug's commercial viability and represents a loss of invested R&D capital.
-0.80A class action lawsuit has been filed alleging that Regeneron executives made false or misleading statements regarding the reliability and statistical validity of the Fianlimab-Libtayo Study. — Securities litigation introduces legal risk, potential settlement costs, and damages management credibility.
-0.40The law firm Robbins Geller Rudman & Dowd LLP has set a September 14, 2026, deadline for investors to seek appointment as lead plaintiff in the Regeneron lawsuit. — This is a procedural legal development that confirms the lawsuit is moving forward but does not change the underlying fundamental failure of the drug trial.
-0.10Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
6h ago
